Hong Kong, China——On May 12, 2021, Viva Biotech (01873.HK) announced that according to the latest semi-annual review results of the world's leading index company MSCI, the company has been included in the MSCI China Small Index constituent stocks. And relevant adjustments will be made after the market closes on May 27, 2021.
The MSCI China Small Cap Index is compiled by MSCI to measure the performance of the small cap segment in the Chinese market, covering companies with good business performance and development potential. The index is widely adopted and referenced by professional investors around the world. The MSCI index will be adjusted quarterly and every six months to maintain authority by adding or removing constituent stocks.
Being included in the MSCI China Small Cap Index is the second time that Viva Biotech has been included in the internationally renowned stock index again after the Hang Seng Hong Kong Stock Connect, the Hang Seng Composite Index, the Hang Seng Hong Kong Listed Biotechnology Index and other indexes, which fully reflects the capital market highly recognizes the company’s two-wheel-drive business model and the development prospects of the one-stop integrated drug R&D and production service platform. It is expected to further expand Viva Biotech’s influence and popularity in the international capital market and introduce more diversified Investor groups.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us